Sagimet Biosciences Inc. SGMT

SGMT Company Overview

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics that target dysfunctional metabolic and fibrotic pathways. The company primarily operates in the biotechnology and pharmaceutical industries, with a strategic emphasis on metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), as well as related liver and metabolic diseases. Its lead product candidate, denifanstat, is an oral selective fatty acid synthase (FASN) inhibitor designed to reduce liver fat accumulation, inflammation, and fibrosis progression.

The company’s primary revenue model is currently centered on research and development activities rather than commercial product sales, as its pipeline remains in clinical development stages. Sagimet has positioned itself around the therapeutic potential of FASN inhibition, which management and public filings describe as a differentiated approach within metabolic disease treatment. The company traces its origins to prior scientific work conducted under the name 3-V Biosciences, before rebranding as Sagimet Biosciences and narrowing its strategic focus toward metabolic and fibrotic disorders. Public filings and investor materials indicate that the company has evolved from a broader infectious disease and oncology orientation into a specialized metabolic disease biotechnology company.